Arch Therapeutics, Inc. (ARTH)
| Market Cap | 22.25M |
| Revenue (ttm) | 10,000 |
| Net Income (ttm) | -5.25M |
| Shares Out | 236.72M |
| EPS (ttm) | -0.03 |
| PE Ratio | n/a |
| Forward PE | 10.75 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $0.0940 |
| Previous Close | $0.0988 |
| Change ($) | -0.0048 |
| Change (%) | -4.86% |
| Day's Open | 0.0847 |
| Day's Range | 0.0831 - 0.0988 |
| Day's Volume | 220,362 |
| 52-Week Range | 0.0780 - 0.2190 |
Medical Industry Veteran with Proven Track Record to Drive Commercialization Effort
FRAMINGHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announc...
FRAMINGHAM, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announc...
Honors for Highest Scoring Poster Abstract in Case Series/Study Category Confirms Commercialization Opportunities for AC5® Advanced Wound System Honors for Highest Scoring Poster Abstract in Case Series...
Company Prepares for Next Stage of Growth Company Prepares for Next Stage of Growth
Additional case studies support the broad potential of AC5® Advanced Wound System in chronic and non-healing wounds Additional case studies support the broad potential of AC5® Advanced Wound System in c...
2021: Executing on Opportunities and Preparing for the Future 2021: Executing on Opportunities and Preparing for the Future
Management to provide corporate update on Dermal Sciences and BioSurgery Management to provide corporate update on Dermal Sciences and BioSurgery
AC5® Advanced Wound System Commercialization Has Commenced AC5® Advanced Wound System Commercialization Has Commenced
FRAMINGHAM, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announc...
FRAMINGHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, announced tod...
Partnership provides US government facilities access and product distribution support Partnership provides US government facilities access and product distribution support
FRAMINGHAM, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, announced tod...
Financing with long-term shareholders provides flexibility during product roll-out Financing with long-term shareholders provides flexibility during product roll-out
Clinical case reports and animal studies that were presented support the broad potential of AC5 Advanced Wound System in a range of complicated acute and chronic wounds Clinical case reports and animal ...
Live moderated video webcast discussion of AC5 Advanced Wound System among management and Key Opinion Leaders on Wednesday, October 28th at 12:00 PM ET Live moderated video webcast discussion of AC5 Adv...
A series of clinical case reports and animal studies support the broad potential of AC5 Advanced Wound System in a range of complicated acute and chronic wounds A series of clinical case reports and ani...
Arch Therapeutics has FDA and EMA approval for AC5.
New York, New York--(Newsfile Corp. - September 22, 2020) - Arch Therapeutics, Inc. (OTCQB: ARTH) has cleared significant hurdles to commercialize its AC5 Advanced Wound System and AC5 Topical Hemostat...
Arch Therapeutics Reports First Pressure Ulcer Case Results
FRAMINGHAM, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today...
FRAMINGHAM, Mass., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today ...
Emerging technology presentation demonstrates use of AC5-GTM in submucosal lifting and management of gastrointestinal bleeding during porcine endoscopic procedures. Emerging technology presentation demo...
Emerging Technology video presentation describing swine studies using AC5-GTM for submucosal lifting and management of gastrointestinal bleeding in endoscopic resection Emerging Technology video present...
Live video moderated discussion with Dr. Terrence Norchi, CEO, on Monday, June 15, at 12:00 PM ET, immediately followed by an interactive Q&A session Live video moderated discussion with Dr. Terrence No...
Financing with long-term shareholders provides flexibility during product roll-out Financing with long-term shareholders provides flexibility during product roll-out
Only funds with coverage >100% are considered.
About ARTH
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company ... [Read more...]
| Industry Biotechnology | Founded 2006 |
| Stock Exchange OTCMKTS | Ticker Symbol ARTH |